Objective:
Evaluate whether AXPAXLI (OTX-TKI) can prevent worsening diabetic retinopathy and vision-threatening complications compared with sham.
Approach:
- Study design: Phase 3 HELIOS-3 compares AXPAXLI with sham, with treatment at baseline and week 48 and follow-up for complications and retinopathy changes.
- Enrollment: The trial is recruiting in Argentina, the United States, and other countries.
Key Findings:
- Dr. Kaiser reported that in earlier studies, patients receiving OTX-TKI had stable or improved diabetic retinopathy over one year.
- He reported that 40% of sham-treated patients developed vision-threatening complications, including proliferative diabetic retinopathy or center-involved diabetic macular edema; none in the OTX-TKI group did.
Interpretation:
HELIOS-3 is intended to assess whether the earlier findings can be replicated using a similar study design.
Limitations:
- The context provides no HELIOS-3 results; the trial is ongoing.
- The earlier-study findings are reported in the interview, without further details about study methods or sample size.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
